Title: “New Developments in Car T Cell Therapy"

Speaker(s):

Shannon Maude, MD, PhD

Assistant Professor of Pediatrics
Children’s Hospital of Philadelphia

Learning Objectives:
1. Identify the most common toxicities of CAR T cell therapies
2. Describe the efficacy and mechanisms of failure of CAR T cell therapies
3. Identify limitations of CAR T cell therapy in AML and solid tumors

Question Title

* 1. Date of Presentation

Question Title

* 2. Your First and Last Name:

Question Title

* 3. Your Email Address:

Question Title

* 4. Month and Day of your Birth

Question Title

* 5. Your Professional Category

Question Title

* 6. Please rate the impact of the following course objectives
As a result of attending this activity, I am better able to:

  Strongly Agree Agree Disagree Strongly Disagree
1. Identify the most common toxicities of CAR T cell therapies
2. Describe the efficacy and mechanisms of failure of CAR T cell therapies
3. Identify limitations of CAR T cell therapy in AML and solid tumors

Question Title

* 7. Please rate the projected impact of this activity on your knowledge, competence, performance, and patient outcomes.
*Competence is defined as the ability to apply knowledge, skills and judgement in practice (knowing how to do something)

  Yes No No Change
The activity increased my knowledge
The activity increased my competence
The activity improved/will improve my performance
The activity will improve my patient outcome

Question Title

* 8. Please rate the speaker on knowledge/content of the presentation

  Excellent Above Average Average Below Average Poor
Rating:

Question Title

* 9. Do you feel this activity was free of commercial bias or influence?
*Commercial bias is defined as a personal judgment in favor of specific product or service of a commercial interest

Question Title

* 10. Do you feel this activity was evidence-based?

Question Title

* 11. Do you plan to make changes to your practice as a result of attending this activity?

Question Title

* 12. Please list suggestions you have for future topics as well as any addition comments.

Question Title

* 13. Are you claiming MOC credit?

If you are not requesting MOC, please scroll to the end of the survey. Otherwise, please check the following attestation and provide your ABP ID number below:

Question Title

* 14. "I give permission to the University of Rochester to share my MOC completion data with the Accreditation Council for Continuing Medical Education (ACCME) and the American Board of Pediatrics (ABP) and transmit the completion data to the ACCME's PARS System on my behalf."

Question Title

* 15. Your ABP ID Number:

In order to receive MOC credit for Grand Rounds, please fill out the correct answers to the two questions below. Credit will be awarded when one of the two questions have been answered correctly.

Question Title

* 16. What is the most common toxicity associated with CD19-directed CAR T cell therapies?

Question Title

* 17. Which of the following is a mechanism of failure of CD19-directed CAR T cell therapies?

Accreditation
The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Certification
The University of Rochester School of Medicine and Dentistry designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification(MOC)
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1 MOC point in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

T